Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2007, Vol. 27 Issue (11): 57-60    DOI:
    
Expression and purification of a targeted cationic polypeptide vector
WANG Hai Hua-mao WANG Jin-jun LI Bi-zhi SHI Zong-hai LI
Download: HTML   PDF(520KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To obtain a targeting cationic polymers (KH)20-EGF and examine its capacity for DNA condensation. Method: Prokaryotic expresssion plasmid pET28a-(KH)20-EGF was constructed and transformed into BL21(DE3). The cationic polypeptide was induced by IPTG and purified using a Ni-NTA column. The purified polypeptide was determined by SDS-PAGE and Western blot analysis. The pDNA package ability of the resulted protein was examined by gel retardation assay. Results: The yield of (KH)20-EGF protein was about 300μg/L. The resulted protein was a little larger than expected when examined by SDS-PAGE and Western blot. Gel retardation assays indicated that (KH)20-EGF can retard the pDNA migration. Conclusion: We successfully expressed the non-virus vector (KH)20-EGF and confirmed its capability of DNA condensation.



Key wordsgene therapy      non-virus vector      cationic polypeptide      expresssion and purification      DNA condensation     
Received: 17 September 2007      Published: 25 November 2007
Corresponding Authors: Zong-hai LI   
Cite this article:

WANG Hai Hua-mao WANG Jin-jun LI Bi-zhi SHI Zong-hai LI. Expression and purification of a targeted cationic polypeptide vector. China Biotechnology, 2007, 27(11): 57-60.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2007/V27/I11/57

[1] ZHAO Xiao-yu,XU Qi-ling,ZHAO Xiao-dong,AN Yun-fei. Enhancing Lentiviral Vector Transduction Efficiency for Facilitating Gene Therapy[J]. China Biotechnology, 2021, 41(8): 52-58.
[2] XU Ying-yong. Current Status and Challenges of Gene Therapy Products[J]. China Biotechnology, 2020, 40(12): 95-103.
[3] CHEN Qing-yu,WANG Xian-zhong,ZHANG Jiao-jiao. Application of Gene Technology in the Treatment of Type 2 Diabetes Mellitus[J]. China Biotechnology, 2020, 40(11): 73-81.
[4] Ya-li HAN,Guang-heng YANG,Yan-wen CHEN,Xiu-li GONG,Jing-zhi ZHANG. The Optimization of Self-deleting Lentiviral Vector Carrying Human β-globin Gene and Promoter[J]. China Biotechnology, 2018, 38(7): 50-57.
[5] LIU Yi-xuan, BIAN Zhen, MA Hong-mei. Progress and Prospect of Cancer Gene Therapy[J]. China Biotechnology, 2016, 36(5): 106-111.
[6] TAO Chang-li, HUANG Shu-lin. Advances in Research on Optimization of Transgenic TCR Pairing in TCR Gene Therapy[J]. China Biotechnology, 2016, 36(3): 87-92.
[7] LIU Rui-qi, WANG Wei-wei, WU Yong-yan, ZHAO Qiu-yun, WANG Yong-sheng, QING Su-zhu. Research Progress of CRISPR-Cas9 and Its Application in Gene Therapy[J]. China Biotechnology, 2016, 36(10): 72-78.
[8] ZHU Shao-yi, GUAN Li-hong, LIN Jun-tang. CRISPR-Cas9 System and Its Applications in Disease Models[J]. China Biotechnology, 2016, 36(10): 79-85.
[9] XUE Jin-feng, XUE Zhi-gang, CHEN Yi-yao, LI Zhuo, YIN Biao, WU Ling-qian, LIANG De-sheng. In vitro and in vivo Gene Therapy Research of CDTK Genes Drove by Enhanced Tumor-specific Promoter in Liver Cancer[J]. China Biotechnology, 2015, 35(6): 1-7.
[10] XUE Yu-wen, LI Tie-jun, ZHOU Jia-ming, CHEN Li. The Application and Perspectives of Multi-target RNAi in the Research and Development of Gene Therapy[J]. China Biotechnology, 2015, 35(1): 75-81.
[11] MA Bu-yun, HE Wan-wan, ZHOU Li, WANG Yi-gang. The Study on Anticancer Effect of Targeting Gene-Virus ZD55-XAF1 in Liver Cancer Xenograft of Mice and Its Safety[J]. China Biotechnology, 2014, 34(1): 15-20.
[12] FAN Fu, CHEN Jian-guo, REN Hong-wei. Development of Gene Therapy for Parkinson’s Disease And Alzheimer’s Disease[J]. China Biotechnology, 2013, 33(4): 129-135.
[13] LIU Si-ye, XIA Hai-bin. A New Targeted Gene Editing Technology Mediated by CRISPR-Cas System[J]. China Biotechnology, 2013, 33(10): 117-123.
[14] CHEN Feng, YANG Yi-shu, ZENG Yi. Current Development on RNA-based Anti-HIV-1 Gene Therapy[J]. China Biotechnology, 2012, 32(6): 93-97.
[15] DIAO Yong, QIU Fei, XIAO Wei-dong. Package Capacity Limit of Recombinant Adeno-associated Virus Vector[J]. China Biotechnology, 2012, 32(01): 97-102.